Revenue: The sum of all revenue fields included for a company's operating activities.
Protalix BioTherapeutics, Inc. (PLX) had Revenue of $10.11M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
|
Revenue |
$10.11M |
$-3.62M |
|
$8.18M |
|
$1.93M |
|
$14.26M |
|
$-4.14M |
|
$0.41M |
|
$-3.73M |
|
$-3.73M |
|
$-3.62M |
|
$-3.62M |
|
$-3.62M |
|
$-3.62M |
|
$-4.14M |
|
$-3.80M |
|
76.61M |
|
76.61M |
|
$-0.05 |
|
$-0.05 |
|
| Balance Sheet Financials | |
$60.51M |
|
$4.72M |
|
$13.38M |
|
$73.89M |
|
$24.32M |
|
-- |
|
$4.36M |
|
$28.68M |
|
$45.21M |
|
$45.21M |
|
$45.21M |
|
78.13M |
|
| Cash Flow Statement Financials | |
$-5.06M |
|
$-0.31M |
|
$5.08M |
|
$19.76M |
|
$19.46M |
|
$-0.30M |
|
$0.54M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.49 |
|
-- |
|
-- |
|
-- |
|
-- |
|
19.11% |
|
-40.99% |
|
-40.99% |
|
-- |
|
-36.90% |
|
-35.79% |
|
$-5.36M |
|
-- |
|
-- |
|
-- |
|
0.14 |
|
0.42 |
|
1.61 |
|
55.76 |
|
-8.01% |
|
-8.01% |
|
-4.90% |
|
-8.01% |
|
$0.58 |
|
$-0.07 |
|
$-0.07 |
|